BR112015012693A2 - derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral - Google Patents
derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viralInfo
- Publication number
- BR112015012693A2 BR112015012693A2 BR112015012693A BR112015012693A BR112015012693A2 BR 112015012693 A2 BR112015012693 A2 BR 112015012693A2 BR 112015012693 A BR112015012693 A BR 112015012693A BR 112015012693 A BR112015012693 A BR 112015012693A BR 112015012693 A2 BR112015012693 A2 BR 112015012693A2
- Authority
- BR
- Brazil
- Prior art keywords
- viral disease
- amelioration
- prevention
- treatment
- pyrimidone derivatives
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000003612 virological effect Effects 0.000 title abstract 3
- 230000002265 prevention Effects 0.000 title abstract 2
- 150000008318 pyrimidones Chemical class 0.000 title abstract 2
- 229940126523 co-drug Drugs 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361750017P | 2013-01-08 | 2013-01-08 | |
| PCT/EP2014/050165 WO2014108406A1 (en) | 2013-01-08 | 2014-01-07 | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112015012693A2 true BR112015012693A2 (pt) | 2017-07-11 |
Family
ID=50070507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015012693A BR112015012693A2 (pt) | 2013-01-08 | 2014-01-07 | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9045486B2 (https=) |
| EP (1) | EP2943495B1 (https=) |
| JP (1) | JP2016518305A (https=) |
| KR (1) | KR20150103285A (https=) |
| CN (1) | CN104918942A (https=) |
| AR (1) | AR094378A1 (https=) |
| AU (1) | AU2014204889A1 (https=) |
| BR (1) | BR112015012693A2 (https=) |
| CA (1) | CA2894642A1 (https=) |
| CL (1) | CL2015001916A1 (https=) |
| CR (1) | CR20150337A (https=) |
| EA (1) | EA201591291A1 (https=) |
| HK (1) | HK1211286A1 (https=) |
| IL (1) | IL239656A0 (https=) |
| MA (1) | MA38323B1 (https=) |
| MX (1) | MX2015008293A (https=) |
| PE (1) | PE20151722A1 (https=) |
| PH (1) | PH12015501517A1 (https=) |
| SG (1) | SG11201503946UA (https=) |
| TW (1) | TW201443053A (https=) |
| WO (1) | WO2014108406A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL239682B (en) | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | History of benzylamine and 2-(aminomethyl)pyridine |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| WO2015038655A1 (en) | 2013-09-12 | 2015-03-19 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| WO2016145103A1 (en) | 2015-03-11 | 2016-09-15 | Alios Biopharma, Inc. | Aza-pyridone compounds and uses thereof |
| BR112017022550B1 (pt) | 2015-04-28 | 2021-02-23 | Shionogi & Co., Ltd | derivados policíclicos de piridona substituída |
| MX394421B (es) | 2015-04-28 | 2025-03-24 | Shionogi & Co | Derivados de piridona policiclica sustituida y profarmaco de los mismos |
| TW201726678A (zh) | 2015-10-30 | 2017-08-01 | 赫孚孟拉羅股份公司 | 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途 |
| AU2016374416A1 (en) | 2015-12-15 | 2018-06-14 | Shionogi & Co., Ltd. | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
| WO2017109088A1 (en) | 2015-12-23 | 2017-06-29 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| ES2881776T3 (es) | 2016-03-08 | 2021-11-30 | Novartis Ag | Compuestos tricíclicos útiles para tratar las infecciones por ortomixovirus |
| WO2017158147A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| WO2017158151A1 (en) | 2016-03-18 | 2017-09-21 | Savira Pharmaceuticals Gmbh | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| JP6961963B2 (ja) * | 2016-04-01 | 2021-11-05 | 三菱ケミカル株式会社 | フルフラールの製造方法 |
| EP3458455B1 (en) * | 2016-05-20 | 2021-06-16 | F. Hoffmann-La Roche AG | Novel pyrazine compounds with oxygen, sulfur and nitrogen linker for the treatment of infectious diseases |
| IL263235B (en) | 2016-05-31 | 2022-07-01 | Kalvista Pharmaceuticals Ltd | History of pyrazoles as plasma kallikrein inhibitors |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| RU2727962C1 (ru) | 2016-08-10 | 2020-07-28 | Сионоги Энд Ко., Лтд. | Фармацевтические композиции, содержащие замещенные полициклические пиридоновые производные и их пролекарство |
| JOP20170169A1 (ar) | 2016-08-29 | 2019-01-30 | Novartis Ag | مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو |
| HUE057912T2 (hu) | 2017-11-29 | 2022-06-28 | Kalvista Pharmaceuticals Ltd | Plazma kallikrein inhibitort tartalmazó dózisformák |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| KR20230031990A (ko) | 2018-02-28 | 2023-03-07 | 노파르티스 아게 | 인플루엔자의 치료를 위한 오르토믹소바이러스 복제의 억제제로서의 10-(디(페닐)메틸)-4-히드록시-8,9,9a,10-테트라히드로-7h-피롤로[1',2':4,5]피라지노[1,2-b]피리다진-3,5-디온 유도체 및 관련 화합물 |
| WO2021028645A1 (en) | 2019-08-09 | 2021-02-18 | Kalvista Pharmaceuticals Limited | Plasma kallikrein inhibitors |
| US20240228495A1 (en) * | 2020-03-25 | 2024-07-11 | Sri International | Tricyclic Inhibitors of Influenza Virus Endonuclease |
| EP4074317A1 (en) | 2021-04-14 | 2022-10-19 | Bayer AG | Phosphorus derivatives as novel sos1 inhibitors |
| WO2024061300A1 (en) * | 2022-09-22 | 2024-03-28 | Insilico Medicine Ip Limited | Inhibitors of trex1 and uses thereof |
| PE20251587A1 (es) | 2022-10-19 | 2025-06-16 | Astrazeneca Ab | 1,3,5-triazinas 2,4,6-trisustituidas como modulares de cx3cr1 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5475109A (en) | 1994-10-17 | 1995-12-12 | Merck & Co., Inc. | Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease |
| WO2005087766A1 (en) | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Hiv integrase inhibitors |
| CN101014572B (zh) | 2004-09-15 | 2011-07-06 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的氨基甲酰基吡啶酮衍生物 |
| TW200716632A (en) | 2005-05-16 | 2007-05-01 | Gilead Sciences Inc | Integrase inhibitor compounds |
| CA2616314A1 (en) * | 2005-07-27 | 2007-02-01 | Gilead Sciences, Inc. | Antiviral phosphonate conjugates for inhibition of hiv |
| TWI518084B (zh) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | 哌喃酮與吡啶酮衍生物之製造方法 |
| US8835461B2 (en) | 2009-03-26 | 2014-09-16 | Shionogi & Co., Ltd. | Substituted 3-hydroxy-4-pyridone derivative |
| LT2444400T (lt) | 2009-06-15 | 2018-06-11 | Shionogi & Co., Ltd. | Pakeistasis policiklinis karbamoilpiridono darinys |
| WO2011000566A2 (en) | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| MX2013003139A (es) | 2010-09-24 | 2013-06-18 | Shionogi & Co | Profarmaco de derivado de carbamoilpiridona policiclica substituida. |
-
2014
- 2014-01-07 CN CN201480004139.1A patent/CN104918942A/zh active Pending
- 2014-01-07 KR KR1020157021361A patent/KR20150103285A/ko not_active Withdrawn
- 2014-01-07 HK HK15112095.2A patent/HK1211286A1/xx unknown
- 2014-01-07 US US14/149,284 patent/US9045486B2/en not_active Expired - Fee Related
- 2014-01-07 MA MA38323A patent/MA38323B1/fr unknown
- 2014-01-07 AR ARP140100051A patent/AR094378A1/es unknown
- 2014-01-07 EA EA201591291A patent/EA201591291A1/ru unknown
- 2014-01-07 MX MX2015008293A patent/MX2015008293A/es unknown
- 2014-01-07 WO PCT/EP2014/050165 patent/WO2014108406A1/en not_active Ceased
- 2014-01-07 BR BR112015012693A patent/BR112015012693A2/pt active Search and Examination
- 2014-01-07 PE PE2015001253A patent/PE20151722A1/es not_active Application Discontinuation
- 2014-01-07 CA CA2894642A patent/CA2894642A1/en not_active Abandoned
- 2014-01-07 SG SG11201503946UA patent/SG11201503946UA/en unknown
- 2014-01-07 AU AU2014204889A patent/AU2014204889A1/en not_active Abandoned
- 2014-01-07 JP JP2015551199A patent/JP2016518305A/ja active Pending
- 2014-01-07 EP EP14703275.9A patent/EP2943495B1/en not_active Not-in-force
- 2014-01-08 TW TW103100719A patent/TW201443053A/zh unknown
-
2015
- 2015-06-25 CR CR20150337A patent/CR20150337A/es unknown
- 2015-06-25 IL IL239656A patent/IL239656A0/en unknown
- 2015-07-03 PH PH12015501517A patent/PH12015501517A1/en unknown
- 2015-07-06 CL CL2015001916A patent/CL2015001916A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2015001916A1 (es) | 2016-01-22 |
| MX2015008293A (es) | 2016-06-02 |
| HK1211286A1 (en) | 2016-05-20 |
| SG11201503946UA (en) | 2015-09-29 |
| CR20150337A (es) | 2015-11-02 |
| AU2014204889A1 (en) | 2015-06-11 |
| EA201591291A1 (ru) | 2015-12-30 |
| EP2943495A1 (en) | 2015-11-18 |
| US9045486B2 (en) | 2015-06-02 |
| PH12015501517A1 (en) | 2015-11-09 |
| IL239656A0 (en) | 2015-08-31 |
| US20140194431A1 (en) | 2014-07-10 |
| MA38323A1 (fr) | 2017-02-28 |
| AR094378A1 (es) | 2015-07-29 |
| EP2943495B1 (en) | 2016-12-28 |
| PE20151722A1 (es) | 2015-11-19 |
| KR20150103285A (ko) | 2015-09-09 |
| TW201443053A (zh) | 2014-11-16 |
| JP2016518305A (ja) | 2016-06-23 |
| HK1212686A1 (en) | 2016-06-17 |
| MA38323B1 (fr) | 2018-05-31 |
| CA2894642A1 (en) | 2014-07-17 |
| CN104918942A (zh) | 2015-09-16 |
| WO2014108406A1 (en) | 2014-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112014029016A8 (pt) | derivados de ácido 7-oxo-tiazolopiridina carbônico e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112014029006A2 (pt) | derivados de 7-oxo-4,7-di-hidro-pirazolo[1,5-a]pirimidina que são úteis no tratamento, melhora ou prevenção de uma doença viral | |
| BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
| BR112014001369A2 (pt) | derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral | |
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| BR112015016184A2 (pt) | derivados de piridona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112015022643A2 (pt) | inibidores diidro-pirrolpiridinona | |
| EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
| EA201690287A1 (ru) | 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом | |
| BR112015020772A2 (pt) | compostos de pirimidina e piridina e seu uso | |
| BR112016005881A2 (pt) | composto, composição farmacêutica e uso do composto | |
| BR112015025766A2 (pt) | derivado de nucleosídeo altamente ativo para o tratamento de hcv | |
| BR112015021983A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| BR112014029185A2 (pt) | nucleosídeos de spirooxetano uracila | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112012023660B8 (pt) | usos de uma quantidade terapeuticamente eficaz de um composto, ou de um sal, solvato, hidrato ou pró-fármaco farmaceuticamente aceitável do mesmo para o tratamento de câncer | |
| BR112015004523A2 (pt) | compostos de tetraciclina | |
| PH12016502353A1 (en) | Pharmaceutical composition | |
| BR112015026967A8 (pt) | fenoxietil di-hidro-1h-isoquinolina, seus usos, e composição farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2495 DE 30-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |